Yin-Hsiu Chien

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1822045/publications.pdf Version: 2024-02-01



YIN-HOUL CHIEN

#	Article	IF	CITATIONS
1	Clinical and molecular features of idiopathic hypogonadotropic hypogonadism in Taiwan: A single center experience. Journal of the Formosan Medical Association, 2022, 121, 218-226.	0.8	8
2	Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Molecular Therapy, 2022, 30, 509-518.	3.7	58
3	CTLA-4 gene mutation and multiple sclerosis: A case report and literature review. Journal of Microbiology, Immunology and Infection, 2022, 55, 545-548.	1.5	3
4	Outcome of Later-Onset Pompe Disease Identified Through Newborn Screening. Journal of Pediatrics, 2022, 244, 139-147.e2.	0.9	10
5	Advanced therapeutic strategy for hereditary neuromuscular diseases. Molecular Therapy, 2022, 30, 12-13.	3.7	1
6	Short stature leads to a diagnosis of Jansen–de Vries syndrome in two unrelated Taiwanese girls: A case report and literature review. Journal of the Formosan Medical Association, 2022, 121, 856-860.	0.8	2
7	Comparison of GATK and DeepVariant by trio sequencing. Scientific Reports, 2022, 12, 1809.	1.6	26
8	Hepatic Steatosis Assessment as a New Strategy for the Metabolic and Nutritional Management of Duchenne Muscular Dystrophy. Nutrients, 2022, 14, 727.	1.7	4
9	OP016: Mini-COMET: Safety and efficacy of ≥97 weeks' avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa. Genetics in Medicine, 2022, 24, S348-S349.	1.1	4
10	eP146: Application of exome sequencing in patients of congenital anomalies with or without intellectual disability. Genetics in Medicine, 2022, 24, S90.	1.1	2
11	Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3. Molecular Genetics and Metabolism Reports, 2022, 31, 100867.	0.4	4
12	Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan. Neurological Sciences, 2022, 43, 4563-4566.	0.9	13
13	Improved diagnosis of citrin deficiency by newborn screening using a molecular second-tier test. Molecular Genetics and Metabolism, 2022, 136, 330-336.	0.5	10
14	CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening. Genetics in Medicine, 2021, 23, 415-420.	1.1	13
15	Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1244-1246.	0.9	12
16	STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa. Journal of Neurology, 2021, 268, 2482-2492.	1.8	21
17	A systematic review of late-onset and very-late-onset multiple acyl-coenzyme A dehydrogenase deficiency: Cohort analysis and patient report from Taiwan. Neuromuscular Disorders, 2021, 31, 218-225.	0.3	3
18	Mini-COMET: effects of avalglucosidase alfa on ptosis in participants with infantile-onset Pompe disease previously treated with alglucosidase alfa. Molecular Genetics and Metabolism, 2021, 132, S137.	0.5	0

#	Article	IF	CITATIONS
19	Rapid Trio Exome Sequencing for Autosomal Recessive Renal Tubular Dysgenesis in Recurrent Oligohydramnios. Frontiers in Genetics, 2021, 12, 606970.	1.1	1
20	Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): A review and classification of <i>GALNS</i> gene variants and reporting of 68 novel variants. Human Mutation, 2021, 42, 1384-1398.	1.1	14
21	A pilot study shows the positive effects of continuous airway pressure for treating hypernasal speech in children with infantile-onset Pompe disease. Scientific Reports, 2021, 11, 18826.	1.6	1
22	RNA-seq of peripheral blood mononuclear cells of congenital generalized lipodystrophy type 2 patients. Scientific Data, 2021, 8, 265.	2.4	3
23	A novel deep intronic variant strongly associates with Alkaptonuria. Npj Genomic Medicine, 2021, 6, 89.	1.7	9
24	Improved Motor Function in Children with AADC Deficiency Treated with Eladocagene Exuparvovec (PTC-AADC): Interim Findings from a Phase 2 Trial. Neuropediatrics, 2021, 52, .	0.3	0
25	Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurology, The, 2021, 20, 1027-1037.	4.9	42
26	Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurology, The, 2021, 20, 1012-1026.	4.9	59
27	Novel Compound Heterozygous Variants in TBCD Gene Associated with Infantile Neurodegenerative Encephalopathy. Children, 2021, 8, 1140.	0.6	3
28	Thyroid disorders in Taiwanese children with Down syndrome: The experience of a single medical center. Journal of the Formosan Medical Association, 2020, 119, 345-349.	0.8	3
29	REM sleep and sleep apnea are associated with language function in Down syndrome children: An analysis of a community sample. Journal of the Formosan Medical Association, 2020, 119, 516-523.	0.8	14
30	Early initiation of high-dose oral ambroxol in combination with enzyme replacement therapy in a neuropathic Gaucher infant. Blood Cells, Molecules, and Diseases, 2020, 81, 102402.	0.6	7
31	Cardiac manifestations and gene mutations of patients with RASopathies in Taiwan. American Journal of Medical Genetics, Part A, 2020, 182, 357-364.	0.7	8
32	Composite Scores of Plasma Tau and β-Amyloids Correlate with Dementia in Down Syndrome. ACS Chemical Neuroscience, 2020, 11, 191-196.	1.7	4
33	Ultrastructural and diffusion tensor imaging studies reveal axon abnormalities in Pompe disease mice. Scientific Reports, 2020, 10, 20239.	1.6	1
34	Survival and diagnostic age of 175 Taiwanese patients with mucopolysaccharidoses (1985–2019). Orphanet Journal of Rare Diseases, 2020, 15, 314.	1.2	16
35	Diversity in heritable disorders of connective tissue at a single center. Connective Tissue Research, 2020, 62, 1-6.	1.1	5
36	Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes. Molecular Genetics & Genomic Medicine, 2020, 8, e1455.	0.6	14

#	Article	IF	CITATIONS
37	Dietary intake and nutritional status of patients with phenylketonuria in Taiwan. Scientific Reports, 2020, 10, 14537.	1.6	5
38	Lessons for the clinical nephrologist: dietary management of adult-onset type II citrullinemia in chronic kidney disease: a nutritional dilemma. Journal of Nephrology, 2020, 33, 1111-1113.	0.9	0
39	Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences. Molecular Genetics and Metabolism Reports, 2020, 23, 100591.	0.4	23
40	Clinical, radiological, and genetic characteristics in patients with Huntington's disease in a Taiwanese cohort. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2020, 183, 352-359.	1.1	1
41	Newborn screening for Morquio disease and other lysosomal storage diseases: results from the 8-plex assay for 70,000 newborns. Orphanet Journal of Rare Diseases, 2020, 15, 38.	1.2	40
42	Development of Newborn Screening for Pompe Disease. International Journal of Neonatal Screening, 2020, 6, 5.	1.2	2
43	The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan. International Journal of Neonatal Screening, 2020, 6, 30.	1.2	1
44	Turner syndrome and cardiovascular anomalies: Care for girls and women. Pediatrics and Neonatology, 2020, 61, 129-130.	0.3	0
45	Monitoring of liver stiffness by transient elastography during the treatment of Gaucher disease. Pediatrics and Neonatology, 2019, 60, 221-223.	0.3	2
46	Primary coenzyme Q10 deficiency-7: expanded phenotypic spectrum and a founder mutation in southern Chinese. Npj Genomic Medicine, 2019, 4, 18.	1.7	29
47	<i>GAA</i> variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry. Human Mutation, 2019, 40, 2146-2164.	1.1	51
48	Heterogeneous nonataxic phenotypes of spinocerebellar ataxia in a Taiwanese population. Brain and Behavior, 2019, 9, e01414.	1.0	10
49	Genotypic and phenotypic correlations of biotinidase deficiency in the Chinese population. Orphanet Journal of Rare Diseases, 2019, 14, 6.	1.2	15
50	Clinical features of Pompe disease with motor neuronopathy. Neuromuscular Disorders, 2019, 29, 903-906.	0.3	7
51	Fabry disease cardiac variant IVS4+919 G>A is associated with multiple cardiac gene variants in patients with severe cardiomyopathy and fatal arrhythmia. Genetics in Medicine, 2019, 21, 1890-1891.	1.1	3
52	Reply to Lutz-Bonengel et al.: Biparental mtDNA transmission is unlikely to be the result of nuclear mitochondrial DNA segments. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1823-1824.	3.3	15
53	Rare Concurrence of Two Congenital Disorders: Miller-Dieker Syndrome and T-Cell Lymphopenia. Cytogenetic and Genome Research, 2019, 157, 227-230.	0.6	0
54	High incidence of coâ€existing GLA variants and stroke susceptibility. European Journal of Neurology, 2019, 26, e70-e70.	1.7	0

#	Article	IF	CITATIONS
55	International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria. Molecular Genetics and Metabolism, 2019, 127, 1-11.	0.5	44
56	Gene therapy improves brain white matter in aromatic lâ€amino acid decarboxylase deficiency. Annals of Neurology, 2019, 85, 644-652.	2.8	30
57	Methylmalonic acidemia/propionic acidemia – the biochemical presentation and comparing the outcome between liver transplantation versus non-liver transplantation groups. Orphanet Journal of Rare Diseases, 2019, 14, 73.	1.2	26
58	Decreased plasma l-arginine levels in organic acidurias (MMA and PA) and decreased plasma branched-chain amino acid levels in urea cycle disorders as a potential cause of growth retardation: Options for treatment. Molecular Genetics and Metabolism, 2019, 126, 397-405.	0.5	26
59	Front Cover, Volume 40, Issue 11. Human Mutation, 2019, 40, i.	1.1	0
60	Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients With Severe Illnesses*. Pediatric Critical Care Medicine, 2019, 20, 1021-1026.	0.2	29
61	Next-generation sequencing identifies TRPV4-related skeletal dysplasia in a boy with progressive bowlegs. Pediatrics and Neonatology, 2019, 60, 102-104.	0.3	3
62	A review of aromatic <scp> </scp> â€amino acid decarboxylase (AADC) deficiency in Taiwan. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2019, 181, 226-229.	0.7	12
63	Electrical Abnormalities in Dopaminergic Neurons of the Substantia Nigra in Mice With an Aromatic L-Amino Acid Decarboxylase Deficiency. Frontiers in Cellular Neuroscience, 2019, 13, 9.	1.8	3
64	Mycobacterium abscessus infection in a boy with X-linked anhidrotic ectodermal dysplasia, immunodeficiency. Journal of Microbiology, Immunology and Infection, 2019, 52, 504-506.	1.5	4
65	Congenital generalized lipodystrophy in Taiwan. Journal of the Formosan Medical Association, 2019, 118, 142-147.	0.8	11
66	Newborn screening: Taiwanese experience. Annals of Translational Medicine, 2019, 7, 281-281.	0.7	23
67	AGIL-AADC Gene Therapy Results in Sustained Improvements in Motor and Developmental Milestones over 5 Years in Children with AADC Deficiency. Neuropediatrics, 2019, 50, .	0.3	0
68	SHOX deficiency in short Taiwanese children: A single-center experience. Journal of the Formosan Medical Association, 2018, 117, 909-914.	0.8	6
69	Functional independence of Taiwanese children with Prader–Willi syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 1309-1314.	0.7	2
70	Clinical characteristics of Taiwanese children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency detected by neonatal screening. Journal of the Formosan Medical Association, 2018, 117, 126-131.	0.8	10
71	A Neuron-Specific Gene Therapy Relieves Motor Deficits in Pompe Disease Mice. Molecular Neurobiology, 2018, 55, 5299-5309.	1.9	28
72	Performance of the Four-Plex Tandem Mass Spectrometry Lysosomal Storage Disease Newborn Screening Test: The Necessity of Adding a 2nd Tier Test for Pompe Disease. International Journal of Neonatal Screening, 2018, 4, 41.	1.2	17

#	Article	IF	CITATIONS
73	Biparental Inheritance of Mitochondrial DNA in Humans. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 13039-13044.	3.3	349
74	Results of Fabry Disease Screening in Male Pre-End Stage Renal Disease Patients with Unknown Etiology Found Through the Platform of a Chronic Kidney Disease Education Program in a Northern Taiwan Medical Center. Kidney and Blood Pressure Research, 2018, 43, 1636-1645.	0.9	23
75	Disease progression in a preâ€symptomatically treated patient with juvenileâ€onset Pompe disease – need for an earlier treatment?. European Journal of Neurology, 2018, 25, e111.	1.7	5
76	Clinical characteristics and surgical history of Taiwanese patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). Orphanet Journal of Rare Diseases, 2018, 13, 89.	1.2	10
77	Russell–Silver syndrome presenting with ambiguous genitalia. Journal of the Formosan Medical Association, 2017, 116, 645-646.	0.8	2
78	Longitudinal follow-up to evaluate speech disorders in early-treated patients with infantile-onset Pompe disease. European Journal of Paediatric Neurology, 2017, 21, 485-493.	0.7	14
79	Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease. Molecular Genetics and Metabolism Reports, 2017, 11, 31-35.	0.4	10
80	Risk assessments in infants suspect having later-onset Pompe disease identified through newborn screening. Molecular Genetics and Metabolism, 2017, 120, S36.	0.5	0
81	Genetic epidemiological study doesn't support GLA IVS4 + 919G > A variant is a significant mutation in Fabry disease. Molecular Genetics and Metabolism, 2017, 121, 22-27.	0.5	9
82	Natural History of Aromatic l-Amino Acid Decarboxylase Deficiency in Taiwan. JIMD Reports, 2017, 40, 1-6.	0.7	26
83	Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. The Lancet Child and Adolescent Health, 2017, 1, 265-273.	2.7	96
84	Presymptomatic Diagnosis of Spinal Muscular Atrophy Through Newborn Screening. Journal of Pediatrics, 2017, 190, 124-129.e1.	0.9	113
85	A Review of Biomarkers for Alzheimer's Disease in Down Syndrome. Neurology and Therapy, 2017, 6, 69-81.	1.4	19
86	Consensus recommendations for the diagnosis, treatment and followâ€up of inherited methylation disorders. Journal of Inherited Metabolic Disease, 2017, 40, 5-20.	1.7	47
87	Gestational age, not transient hyperthyrotropinemia impacts brain white matter diffusion tensor imaging in premature infants. Experimental and Therapeutic Medicine, 2017, 15, 1013-1020.	0.8	1
88	Newborn Screening for Severe Combined Immunodeficiency in Taiwan. International Journal of Neonatal Screening, 2017, 3, 16.	1.2	38
89	Family History of Early Infant Death Correlates with Earlier Age at Diagnosis But Not Shorter Time to Diagnosis for Severe Combined Immunodeficiency. Frontiers in Immunology, 2017, 8, 808.	2.2	34
90	AB104. Evaluation of a new non-derivatized MS/MS kit in newborn screening program. Annals of Translational Medicine, 2017, 5, AB104-AB104.	0.7	1

#	Article	IF	CITATIONS
91	Slow, progressive myopathy in neonatally treated patients with infantile-onset Pompe disease: a muscle magnetic resonance imaging study. Orphanet Journal of Rare Diseases, 2016, 11, 63.	1.2	23
92	Causes of death and clinical characteristics of 34 patients with Mucopolysaccharidosis II in Taiwan from 1995–2012. Orphanet Journal of Rare Diseases, 2016, 11, 85.	1.2	26
93	372. U1 snRNA-Mediated Correction of a Splicing Error of the Dopa Decarboxylase Gene. Molecular Therapy, 2016, 24, S149.	3.7	0
94	3-O-methyldopa levels in newborns: Result of newborn screening for aromatic l-amino-acid decarboxylase deficiency. Molecular Genetics and Metabolism, 2016, 118, 259-263.	0.5	52
95	Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series. Molecular Genetics and Metabolism Reports, 2016, 7, 63-69.	0.4	27
96	Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency. European Journal of Medicinal Chemistry, 2016, 123, 14-20.	2.6	15
97	Integrated care for Down syndrome. Congenital Anomalies (discontinued), 2016, 56, 104-106.	0.3	2
98	Advances in newborn screening for Pompe disease and resulting clinical outcomes. Expert Opinion on Orphan Drugs, 2016, 4, 21-29.	0.5	0
99	Measuring propionyl-CoA carboxylase activity in phytohemagglutinin stimulated lymphocytes using high performance liquid chromatography. Clinica Chimica Acta, 2016, 453, 13-20.	0.5	5
100	Long-term outcome for Down syndrome patients with hematopoietic disorders. Journal of the Formosan Medical Association, 2016, 115, 94-99.	0.8	5
101	Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer's Disease. Frontiers in Aging Neuroscience, 2016, 8, 316.	1.7	44
102	201. Neuron-Specific Systemic Gene Therapy for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency. Molecular Therapy, 2015, 23, S80.	3.7	0
103	C-11. An Update on Gene Therapy for the Treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency. Molecular Therapy, 2015, 23, S103.	3.7	0
104	Mudd's disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotes. Orphanet Journal of Rare Diseases, 2015, 10, 99.	1.2	39
105	Survival and Developmental Milestones Among Pompe Registry Patients with Classic Infantile-Onset Pompe Disease with Different Timing of Initiation of Treatment with Enzyme Replacement Therapy. Journal of Neuromuscular Diseases, 2015, 2, S61-S62.	1.1	5
106	The Pompe Registry: 10 Years of Data. Journal of Neuromuscular Diseases, 2015, 2, S22-S23.	1.1	2
107	Congenital Malformations in Newborns—A Challenge Unmet for Decades. Pediatrics and Neonatology, 2015, 56, 5-6.	0.3	0
108	Long-Term Prognosis of Patients with Infantile-Onset Pompe Disease Diagnosed by Newborn Screening and Treated since Birth. Journal of Pediatrics, 2015, 166, 985-991.e2.	0.9	113

#	Article	IF	CITATIONS
109	The Pompe Registry: 10years of data. Molecular Genetics and Metabolism, 2015, 114, S65.	0.5	Ο
110	Benefits of Neuronal Preferential Systemic Gene Therapy for Neurotransmitter Deficiency. Molecular Therapy, 2015, 23, 1572-1581.	3.7	25
111	Mortality, disability, and intensive care in patients with mitochondrial 3243A>G mutation. Intensive Care Medicine, 2015, 41, 1493-1495.	3.9	1
112	X-linked hyper-IgM syndrome with CD40LG mutation: Two case reports and literature review in Taiwanese patients. Journal of Microbiology, Immunology and Infection, 2015, 48, 113-118.	1.5	25
113	Incidence of severe combined immunodeficiency through newborn screening in a Chinese population. Journal of the Formosan Medical Association, 2015, 114, 12-16.	0.8	68
114	The Pompe Registry: 10 Years of Data. Journal of Neuromuscular Diseases, 2015, 2, S22-S23.	1.1	1
115	Survival and Developmental Milestones Among Pompe Registry Patients with Classic Infantile-Onset Pompe Disease with Different Timing of Initiation of Treatment with Enzyme Replacement Therapy. Journal of Neuromuscular Diseases, 2015, 2, S61-S62.	1.1	2
116	Hypertrophic Cardiomyopathy in Pompe Disease Is Not Limited to the Classic Infantile-Onset Phenotype. JIMD Reports, 2014, 17, 71-75.	0.7	30
117	Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile- and Late-Onset Pompe Disease Identified by Newborn Screening. JIMD Reports, 2014, 19, 67-73.	0.7	29
118	Treatment of Congenital Neurotransmitter Deficiencies by Intracerebral Ventricular Injection of an Adeno-Associated Virus Serotype 9 Vector. Human Gene Therapy, 2014, 25, 189-198.	1.4	19
119	Prominent vacuolation of the eyelid levator muscle in an earlyâ€treated child with infantileâ€onset Pompe disease. Muscle and Nerve, 2014, 50, 301-302.	1.0	7
120	Parental discussion of G6PD deficiency and child health: implications for clinical practice. Archives of Disease in Childhood, 2014, 99, 251-255.	1.0	1
121	Cyclic Pamidronate Infusion for Neonatal-onset Osteogenesis Imperfecta. Pediatrics and Neonatology, 2014, 55, 306-311.	0.3	11
122	The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients. Acta Neuropathologica Communications, 2014, 2, 2.	2.4	55
123	Efficacy and safety of intermittent hemodialysis in infants and young children with inborn errors of metabolism. Pediatric Nephrology, 2014, 29, 111-116.	0.9	16
124	Diagnosis of aromatic l-amino acid decarboxylase deficiency by measuring 3-O-methyldopa concentrations in dried blood spots. Clinica Chimica Acta, 2014, 431, 19-22.	0.5	29
125	Clinical characteristics and outcomes of primary antibody deficiency: A 20-year follow-up study. Journal of the Formosan Medical Association, 2014, 113, 340-348.	0.8	17
126	Development of a feasible assay for the detection of GAA mutations in patients with Pompe disease. Clinica Chimica Acta, 2014, 429, 18-25.	0.5	7

#	Article	IF	CITATIONS
127	Outcome of early-treated type III Gaucher disease patients. Blood Cells, Molecules, and Diseases, 2014, 53, 105-109.	0.6	22
128	Two Frequent Mutations Associated with the Classic Form of Propionic Acidemia in Taiwan. Biochemical Genetics, 2014, 52, 415-429.	0.8	13
129	AADC Deficiency. , 2014, , 3-4.		0
130	Promising outcomes in glutaric aciduria type I patients detected by newborn screening. Metabolic Brain Disease, 2013, 28, 61-67.	1.4	29
131	Newborn screening for citrin deficiency and carnitine uptake defect using second-tier molecular tests. BMC Medical Genetics, 2013, 14, 24.	2.1	22
132	Lysoâ€globotriaosylsphingosine (lysoâ€Gb ₃) levels in neonates and adults with the Fabry disease laterâ€onset <i>GLA</i> IVS4+919G>A mutation. Journal of Inherited Metabolic Disease, 2013, 36, 881-885.	1.7	18
133	Regulation of the dopaminergic system in a murine model of aromatic l-amino acid decarboxylase deficiency. Neurobiology of Disease, 2013, 52, 177-190.	2.1	37
134	Pompe Disease: Early Diagnosis and Early Treatment Make a Difference. Pediatrics and Neonatology, 2013, 54, 219-227.	0.3	135
135	AADC Deficiency. Advances in Pharmacology, 2013, 68, 273-284.	1.2	10
136	Carnitine Uptake Defect (Primary Carnitine Deficiency): Risk in Genotype-Phenotype Correlation. Human Mutation, 2013, 34, 655-655.	1.1	13
137	Longâ€ŧerm efficacy of miglustat in paediatric patients with Niemannâ€Pick disease type C. Journal of Inherited Metabolic Disease, 2013, 36, 129-137.	1.7	34
138	Lung toxicity of hydroxypropyl-β-cyclodextrin infusion. Molecular Genetics and Metabolism, 2013, 109, 231-232.	0.5	27
139	Diagnosing mucopolysaccharidosis IVA. Journal of Inherited Metabolic Disease, 2013, 36, 293-307.	1.7	77
140	Clinical application of massively parallel sequencing in the molecular diagnosis of glycogen storage diseases of genetically heterogeneous origin. Genetics in Medicine, 2013, 15, 106-114.	1.1	65
141	Fatty Acid Oxidation Disorders in a Chinese Population in Taiwan. JIMD Reports, 2013, 11, 165-172.	0.7	26
142	Clinical Features and Genetic Analysis of Taiwanese Patients With the Hyper IgM Syndrome Phenotype. Pediatric Infectious Disease Journal, 2013, 32, 1010-1016.	1.1	24
143	Analysis of Lyso-Globotriaosylsphingosine in Dried Blood Spots. Annals of Laboratory Medicine, 2013, 33, 274-278.	1.2	29
144	Myostatin and Insulin-Like Growth Factor I: Potential Therapeutic Biomarkers for Pompe Disease. PLoS ONE, 2013, 8, e71900.	1.1	15

#	Article	IF	CITATIONS
145	Web-Based Newborn Screening System for Metabolic Diseases: Machine Learning Versus Clinicians. Journal of Medical Internet Research, 2013, 15, e98.	2.1	19
146	Enhanced interpretation of newborn screening results without analyte cutoff values. Genetics in Medicine, 2012, 14, 648-655.	1.1	117
147	Association of the Congenital Neuromuscular Form of Glycogen Storage Disease Type IV With a Large Deletion and Recurrent Frameshift Mutation. Journal of Child Neurology, 2012, 27, 204-208.	0.7	15
148	Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Human Molecular Genetics, 2012, 21, 2618-2618.	1.4	0
149	Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer. Journal of Human Genetics, 2012, 57, 130-138.	1.1	21
150	Newborn Screening for Phenylketonuria: Machine Learning vs Clinicians. , 2012, , .		1
151	Diagnosis of Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency Using High-Resolution Melting Analysis and a Clinical Scoring System. Journal of Pediatrics, 2012, 161, 626-631.e2.	0.9	14
152	Late onset of symptoms in an atypical patient with the cblJ inborn error of vitamin B12 metabolism: Diagnosis and novel mutation revealed by exome sequencing. Molecular Genetics and Metabolism, 2012, 107, 664-668.	0.5	33
153	Early Pathologic Changes and Responses to Treatment in Patients With Later-Onset Pompe Disease. Pediatric Neurology, 2012, 46, 168-171.	1.0	21
154	Algorithm for Pompe disease newborn screening: Results from the Taiwan screening program. Molecular Genetics and Metabolism, 2012, 106, 281-286.	0.5	72
155	An acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic delivery. Genetic Vaccines and Therapy, 2012, 10, 3.	1.5	4
156	Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat. Orphanet Journal of Rare Diseases, 2012, 7, 76.	1.2	66
157	A Novel 3670-Base Pair Mitochondrial DNA Deletion Resulting in Multi-systemic Manifestations in a Child. Pediatrics and Neonatology, 2012, 53, 264-268.	0.3	15
158	Application of Mass Spectrometry in Newborn Screening: About Both Small Molecular Diseases and Lysosomal Storage Diseases. Topics in Current Chemistry, 2012, 336, 177-196.	4.0	5
159	Fabry Disease: Incidence of the Common Later-Onset α-Galactosidase A IVS4+919G→A Mutation in Taiwanese Newborns—Superiority of DNA-Based to Enzyme-Based Newborn Screening for Common Mutations. Molecular Medicine, 2012, 18, 780-784.	1.9	71
160	Gene Therapy for Aromatic <scp>l</scp> -Amino Acid Decarboxylase Deficiency. Science Translational Medicine, 2012, 4, 134ra61.	5.8	195
161	Integrating Human Genome Database into Electronic Health Record with Sequence Alignment and Compression Mechanism. Journal of Medical Systems, 2012, 36, 2587-2597.	2.2	7
169	A reliable password-based user authentication scheme for Web-based Human Genome Database System.		0

162 , 2011, , .

#	Article	IF	CITATIONS
163	Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project. Genetics in Medicine, 2011, 13, 230-254.	1.1	308
164	Left Ventricular Geometry, Global Function, and Dyssynchrony in Infants and Children With Pompe Cardiomyopathy Undergoing Enzyme Replacement Therapy. Journal of Cardiac Failure, 2011, 17, 930-936.	0.7	25
165	Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Human Molecular Genetics, 2011, 20, 4851-4864.	1.4	129
166	Distribution, clinical features and treatment in Taiwanese patients with symptomatic primary immunodeficiency diseases (PIDs) in a nationwide population-based study during 1985–2010. Immunobiology, 2011, 216, 1286-1294.	0.8	51
167	Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease. Molecular Genetics and Metabolism, 2011, 102, 57-60.	0.5	9
168	SLC25A13 gene mutations in Taiwanese patients with non-viralhepatocellular carcinoma. Molecular Genetics and Metabolism, 2011, 103, 293-296.	0.5	20
169	Rapid progressive course of later-onset Pompe disease in Chinese patients. Molecular Genetics and Metabolism, 2011, 104, 284-288.	0.5	39
170	Congenital Hypopituitarism due to POU1F1 Gene Mutation. Journal of the Formosan Medical Association, 2011, 110, 58-61.	0.8	10
171	Later-Onset Pompe Disease: Early Detection and Early Treatment Initiation Enabled by Newborn Screening. Journal of Pediatrics, 2011, 158, 1023-1027.e1.	0.9	88
172	Computational analysis of a novel mutation in ETFDH gene highlights its long-range effects on the FAD-binding motif. BMC Structural Biology, 2011, 11, 43.	2.3	24
173	CEREBRAL DIFFUSION TENSOR IMAGES IN INFANTS AND NEONATES WITH INFANTILE ONSET POMPE DISEASE. Biomedical Engineering - Applications, Basis and Communications, 2011, 23, 205-213.	0.3	2
174	Clinical Aspects and Genetic Analysis of Taiwanese Patients with Wiskott–Aldrich Syndrome Protein Mutation: The First Identification of X-Linked Thrombocytopenia in the Chinese with Novel Mutations. Journal of Clinical Immunology, 2010, 30, 593-601.	2.0	14
175	Newborn Screening Healthcare Information System Based on Service-Oriented Architecture. Journal of Medical Systems, 2010, 34, 519-530.	2.2	9
176	Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. Journal of Inherited Metabolic Disease, 2010, 33, 295-305.	1.7	128
177	Newborn screening for neuropathic lysosomal storage disorders. Journal of Inherited Metabolic Disease, 2010, 33, 381-386.	1.7	20
178	Complex rearrangements between chromosomes 6, 10, and 11 with multiple deletions at breakpoints. American Journal of Medical Genetics, Part A, 2010, 152A, 2327-2334.	0.7	14
179	Stabilization of blood methylmalonic acid level in methylmalonic acidemia after liver transplantation. Pediatric Transplantation, 2010, 14, 337-341.	0.5	35
180	Enzyme replacement therapy for mucopolysaccharidosis Vl—experience in Taiwan. Journal of Inherited Metabolic Disease, 2010, 33, 421-427.	1.7	59

#	Article	IF	CITATIONS
181	CCL18 as an alternative marker in Gaucher and Niemann-Pick disease with chitotriosidase deficiency. Blood Cells, Molecules, and Diseases, 2010, 44, 38-40.	0.6	15
182	Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry. Clinica Chimica Acta, 2010, 411, 1428-1431.	0.5	47
183	Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Molecular Genetics and Metabolism, 2010, 99, 379-383.	0.5	91
184	Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening. Molecular Genetics and Metabolism, 2010, 100, 46-50.	0.5	86
185	Reduction in imiglucerase dosage causes immediate rise of chitotriosidase activity in patients with Gaucher disease. Molecular Genetics and Metabolism, 2010, 101, 90-91.	0.5	2
186	Enzymatic activity of methionine adenosyltransferase variants identified in patients with persistent hypermethioninemia. Molecular Genetics and Metabolism, 2010, 101, 172-177.	0.5	28
187	Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Molecular Genetics and Metabolism, 2010, 101, 324-331.	0.5	69
188	Reversal of Cardiac Dysfunction after Enzyme Replacement in Patients with Infantile-Onset Pompe Disease. Journal of Pediatrics, 2009, 155, 271-275.e2.	0.9	56
189	Caloric restriction in Alström syndrome prevents hyperinsulinemia. American Journal of Medical Genetics, Part A, 2009, 149A, 666-668.	0.7	16
190	Identification of novel mutations in the <i>SLC25A15</i> gene in hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome: A clinical, molecular, and functional study. Human Mutation, 2009, 30, 741-748.	1.1	57
191	Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset <i>GLA</i> mutation c.936+919G>A (IVS4+919G>A). Human Mutation, 2009, 30, 1397-1405.	1.1	299
192	Pseudogeneâ€derived <i>IKBKG</i> gene mutations in incontinentia pigmenti. Clinical Genetics, 2009, 76, 417-419.	1.0	6
193	Cystathionine γ-lyase: Clinical, metabolic, genetic, and structural studies. Molecular Genetics and Metabolism, 2009, 97, 250-259.	0.5	57
194	Schizencephaly in LEOPARD Syndrome. Pediatric Neurology, 2009, 41, 71-73.	1.0	4
195	Glycogen Storage Disease Type Ib: The First Case in Taiwan. Pediatrics and Neonatology, 2009, 50, 125-128.	0.3	3
196	X-linked Liver Glycogenosis in a Taiwanese Family: Transmission From Undiagnosed Males. Pediatrics and Neonatology, 2009, 50, 230-233.	0.3	6
197	Pompe Disease in Infants: Improving the Prognosis by Newborn Screening and Early Treatment. Pediatrics, 2009, 124, e1116-e1125.	1.0	185
198	Newborn Screening System Based on Adaptive Feature Selection and Support Vector Machines. , 2009, ,		2

#	Article	IF	CITATIONS
199	A Multi Model Voting Enhancement for Newborn Screening Healthcare Information System. Studies in Computational Intelligence, 2009, , 481-492.	0.7	Ο
200	Eye anomalies and neurological manifestations in patients with PAX6 mutations. Molecular Vision, 2009, 15, 2139-45.	1.1	19
201	Novel human pathological mutations. Gene symbol: GLA. Disease: Fabry disease. Human Genetics, 2009, 125, 336.	1.8	1
202	Novel human pathological mutations. Gene symbol: GLA. Disease: Fabry disease. Human Genetics, 2009, 125, 336.	1.8	5
203	Acute metabolic decompensation and sudden death in Barth syndrome: report of a family and a literature review. European Journal of Pediatrics, 2008, 167, 941-944.	1.3	47
204	A Promoter Sequence Variant of ZNF750 Is Linked with Familial Psoriasis. Journal of Investigative Dermatology, 2008, 128, 1662-1668.	0.3	35
205	Torsade de pointes ventricular tachycardia during elective intubation in a patient with Pompe disease. Paediatric Anaesthesia, 2008, 18, 346-348.	0.6	7
206	Transcatheter Closure of Portal-Systemic Shunt Combining Congenital Double Extrahepatic Inferior Vena Cava with Vascular Plug. Journal of Pediatrics, 2008, 153, 723.	0.9	10
207	Detection and imaging of non-contractile inclusions and sarcomeric anomalies in skeletal muscle by second harmonic generation combined with two-photon excited fluorescence. Journal of Structural Biology, 2008, 162, 500-508.	1.3	48
208	Brain Damage by Mild Metabolic Derangements in Methylmalonic Acidemia. Pediatric Neurology, 2008, 39, 325-329.	1.0	24
209	Screening for pompe disease and fabry disease. Clinical Therapeutics, 2008, 30, S77-S77.	1.1	1
210	Early Detection of Glutaric Aciduria Type I by Newborn Screening in Taiwan. Journal of the Formosan Medical Association, 2008, 107, 139-144.	0.8	18
211	Early Detection of Pompe Disease by Newborn Screening Is Feasible: Results From the Taiwan Screening Program. Pediatrics, 2008, 122, e39-e45.	1.0	207
212	A Newborn Screening System Based on Service-Oriented Architecture Embedded Support Vector Machine. , 2008, , .		1
213	Myopathy in Gaucher disease. Journal of Inherited Metabolic Disease, 2008, 31, 489-491.	1.7	4
214	Clinical Aspects and Molecular Analysis of Chinese Patients with Wiskott-Aldrich Syndrome in Taiwan. International Archives of Allergy and Immunology, 2008, 145, 15-23.	0.9	7
215	Chubby Face and the Biochemical Parameters for the Early Diagnosis of Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency. Journal of Pediatric Gastroenterology and Nutrition, 2008, 47, 187-192.	0.9	19
216	Changes in incidence and sex ratio of glucose-6-phosphate dehydrogenase deficiency by population drift in Taiwan. Southeast Asian Journal of Tropical Medicine and Public Health, 2008, 39, 154-61.	1.0	3

#	Article	IF	CITATIONS
217	Deconstructing Pompe Disease by Analyzing Single Muscle Fibers: "To See a World in a Grain of Sand…― Autophagy, 2007, 3, 546-552.	4.3	102
218	Recombinant human acid Â-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology, 2007, 68, 99-109.	1.5	696
219	Slipped Capital Femoral Epiphysis as a Complication of Growth Hormone Therapy. Journal of the Formosan Medical Association, 2007, 106, S46-S50.	0.8	12
220	The Design and Implementation of a Next Generation Information System for Newborn Screening. , 2007, , .		4
221	Identification and management of cardiac perforation from a double lumen catheter in an infant. Paediatric Anaesthesia, 2007, 17, 500-502.	0.6	2
222	Deficiency of the carnitine transporter (OCTN2) with partial N-acetylglutamate synthase (NACS) deficiency. Journal of Inherited Metabolic Disease, 2007, 30, 816-816.	1.7	11
223	Treatment of Niemann–Pick disease type C in two children with miglustat: Initial responses and maintenance of effects over 1Âyear. Journal of Inherited Metabolic Disease, 2007, 30, 826-826.	1.7	42
224	The Genetics of Atopic Dermatitis. Clinical Reviews in Allergy and Immunology, 2007, 33, 178-190.	2.9	25
225	A review of treatment of Pompe disease in infants. Biologics: Targets and Therapy, 2007, 1, 195-201.	3.0	7
226	Tandem Mass Neonatal Screening in Taiwan—Report from One Center. Journal of the Formosan Medical Association, 2006, 105, 882-886.	0.8	32
227	De novo mutation in the BTK gene of atypical X-linked agammaglobulinemia in a patient with recurrent pyoderma. Annals of Allergy, Asthma and Immunology, 2006, 96, 744-748.	0.5	18
228	Time course of acylcarnitine elevation in neonatal intrahepatic cholestasis caused by citrin deficiency. Journal of Inherited Metabolic Disease, 2006, 29, 551-555.	1.7	17
229	Identification of variations in the human phosphoinositide 3-kinase p110? gene in children with primary B-cell immunodeficiency of unknown aetiology. International Journal of Immunogenetics, 2006, 33, 361-369.	0.8	48
230	Brain Development in Infantile-Onset Pompe Disease Treated by Enzyme Replacement Therapy. Pediatric Research, 2006, 60, 349-352.	1.1	75
231	Spectrum of hypermethioninemia in neonatal screening. Early Human Development, 2005, 81, 529-533.	0.8	32
232	Mapping of psoriasis to 17q terminus. Journal of Medical Genetics, 2005, 42, 152-158.	1.5	38
233	Plasma chitotriosidase activity and malaria. Clinica Chimica Acta, 2005, 353, 215.	0.5	17
234	KIF21A gene c.2860C>T mutation in congenital fibrosis of extraocular muscles type 1 and 3. Molecular Vision, 2005, 11, 245-8.	1.1	16

#	Article	IF	CITATIONS
235	Poor Outcome for Neonatal-Type Nonketotic Hyperglycinemia Treated With High-Dose Sodium Benzoate and Dextromethorphan. Journal of Child Neurology, 2004, 19, 39-42.	0.7	48
236	Rapid detection of FGFR3 gene mutation in achondroplasia by DHPLC system-coupling heteroduplex and fluorescence-enhanced primer-extension analysis. Journal of Human Genetics, 2004, 49, 399-403.	1.1	11
237	Distal arthrogryposis in two sisters born to different fathers. American Journal of Medical Genetics Part A, 2004, 125A, 100-101.	2.4	6
238	Mutation spectrum in Taiwanese patients with phenylalanine hydroxylase deficiency and a founder effect for the R241C mutation. Human Mutation, 2004, 23, 206-206.	1.1	28
239	Diffusion tensor images in children with early-treated, chronic, malignant phenylketonuric: correlation with intelligence assessment. American Journal of Neuroradiology, 2004, 25, 1569-74.	1.2	17
240	Carbohydrate deficient glycoprotein syndrome type Ia. Journal of the Formosan Medical Association, 2004, 103, 721-3.	0.8	1
241	Molecular diagnosis of Wiskott-Aldrich syndrome in Taiwan. Journal of Microbiology, Immunology and Infection, 2004, 37, 276-81.	1.5	5
242	Gene symbol: WAS. Disease: Wiskott-Aldrich syndrome. Human Genetics, 2004, 115, 531.	1.8	0
243	Gene symbol: WAS. Disease: Wiskott-Aldrich syndrome. Human Genetics, 2004, 115, 532.	1.8	Ο
244	Gene symbol: WAS. Disease: Wiskott-Aldrich syndrome. Human Genetics, 2004, 115, 532.	1.8	0
245	Gene symbol: WAS. Disease: Wiskott-Aldrich syndrome. Human Genetics, 2004, 115, 534.	1.8	1
246	Mutations. Human Genetics, 2003, 113, 365-366.	1.8	5
247	Mutations. Human Genetics, 2003, 113, 367-368.	1.8	3
248	Common variable immunodeficiency with hypoglycemia, Kikuchi lymphadenitis, and hemiparesis in two siblings. Journal of Microbiology, Immunology and Infection, 2003, 36, 65-8.	1.5	0
249	Association between levels of TNF-alpha and TNF-alpha promoter -308 A/A polymorphism in children with Kawasaki disease. Journal of the Formosan Medical Association, 2003, 102, 147-50.	0.8	25
250	Gene symbol: btk. Disease: Bruton agammaglobulinemia. Human Genetics, 2003, 113, 366.	1.8	0
251	Rehospitalization of extremely-low-birth-weight infants in first 2 years of life. Early Human Development, 2002, 66, 33-40.	0.8	44
252	Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. Journal of Inherited Metabolic Disease, 2002, 25, 593-595.	1.7	10

#	Article	IF	CITATIONS
253	Cranial MR spectroscopy of tetrahydrobiopterin deficiency. American Journal of Neuroradiology, 2002, 23, 1055-8.	1.2	11
254	Cockayne syndrome in a family. Acta Paediatrica Taiwanica = Taiwan Er Ke Yi Xue Hui Za Zhi, 2002, 43, 46-9.	0.1	0
255	DiGeorge sequence with hypogammaglobulinemia: a case report. Journal of Microbiology, Immunology and Infection, 2002, 35, 187-90.	1.5	2
256	Neonatal screening for congenital adrenal hyperplasia in Taiwan: a pilot study. Journal of the Formosan Medical Association, 2002, 101, 691-4.	0.8	11
257	An infant with heart murmur and dysmorphic face. Acta Paediatrica Taiwanica = Taiwan Er Ke Yi Xue Hui Za Zhi, 2002, 43, 241-3.	0.1	0
258	Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease. Journal of the Formosan Medical Association, 2002, 101, 627-31.	0.8	5
259	Treatment and outcome of Taiwanese patients with 6-pyruvoyltetrahydropterin synthase gene mutations. Journal of Inherited Metabolic Disease, 2001, 24, 815-823.	1.7	27
260	Congenital intracranial teratoma. Pediatric Neurology, 2000, 22, 72-74.	1.0	45
261	DNA mixture interpretation using linear regression and neural networks on massively parallel sequencing data of single nucleotide polymorphisms. Australian Journal of Forensic Sciences, 0, , 1-13.	0.7	2